Mylan Pharmaceuticals Inc

7 in Phase 3

Quick facts

Founded	1961

Bevacizumab as Avastin · Oncology
Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.
Bevacizumab as MYL-1402O · Oncology
MYL-1402O is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.
Estrace® 0.01% cream · Gynecology / Endocrinology
Estrace cream delivers estradiol, a natural estrogen, directly to vaginal and vulvar tissues to relieve symptoms of atrophic vaginitis and urogenital atrophy.
Estradiol Vaginal Cream, 0.01% · Gynecology / Menopause
Estradiol vaginal cream delivers the hormone estrogen directly to vaginal tissues to relieve symptoms of vaginal atrophy and genitourinary syndrome of menopause.
MYL-1701P · Oncology
MYL-1701P is a biosimilar of pegfilgrastim that stimulates neutrophil production to prevent chemotherapy-induced neutropenia.
MYL-1701P, a proposed biosimilar to Eylea · Ophthalmology
MYL-1701P is a biosimilar to aflibercept that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit pathological neovascularization in the eye.
Transdermal system containing progestin · Contraception / Women's Health
A transdermal progestin delivery system that releases the hormone through the skin to provide contraceptive and/or hormone replacement effects.

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: